Century Therapeutics Inc. has announced its first program for type 1 diabetes, CNTY-813. The program comprises induced pluripotent stem cell (iPSC)-derived β islets engineered with the company’s proprietary Allo-Evasion 5.0 technology, designed to protect from T-cell, NK-cell and humoral immune rejection, with the goal of durable glycemic control without the need for systemic immunosuppression.